Wednesday, April 26, 2006

 

Pharmaceutical Companies Trying To Hook THe Nation?

'The N.H.S. Wastes Money on Medication which the Pharmaceutical Companies Know Does Not Cure'
 
Drugs watchdog accuses big pharmaceutical companies of trying to hook the nation onto medical drugs - for life.
 
[ClickPress, Wed Apr 26 2006] At a Sussex drugs conference today, C.E.P.T.A. Founder Kenneth Eckersley said that whilst waste occurs in many forms, probably the greatest waste is when we buy something, or pay someone, to do a job – “and we don’t get the promised result.”
 
“This”, he said “is the underlying problem in the NHS, which is comprised of premises, equipment, staff, ‘advisors’, treatment, medication and patients, and the number of patients and the frequency of their treatments control premises and equipment, the size of staff, the millions spent on advisors, and the quantities of medication taxpayers pay for.”
 
“However, the numbers of patients and treatments increase each year. Not because of immigration or increasing life expectancy which are blamed, but mainly because prescription “cures” have been replaced by “treatment programmes” offering “support” – based on ‘treatment’ for life.”
 
Eckersley pointed out that a century ago; “treatment” was nearly synonymous with “cure”. Then the pharmaceuticals realised that curing patients was losing them customers, whilst shareholders were demanding that, like other businesses, they should seek to increasingly sell more at greater profit.
 
Medication industry strategies have, over the last half century, moved away from “cure” and concentrated upon continuous “support” programmes based on frequent prescribing of pharmaceutical drugs to more and more population. As a result, a majority of patients are not getting cured. Treatments they receive keep them “stable”, give them “support” and make them “feel cared for”. But without a cure, the numbers of patients and drug doses rise every week.
 
“Consequently,” stressed Eckersley, “billions of pounds spent to keep our nation healthy are not buying the real health expected. Instead we are buying “a feel good factor” in the form of a pair of psycho-pharmaceutical crutches for which we will go on paying, and hobble along on - for the rest of our lives.”
 
“If we had cures” claimed Eckersley, we would need fewer hospitals, equipment and staff. We don’t get cures because the psycho-pharms have chosen to avoid ‘cure medication’ which shortens their consumer list, and instead deliver ‘maintenance’, which escalates the number of patients and treatment doses.
 
It is that industry’s avoidance of cure medication delivery which is the under-lying waste factor in the NHS today, because it creates waste in all sectors.
 
“Don’t blame government, buildings or equipment, and don’t blame the over-worked staff” said Eckersley. “Instead, ban prescription of all habit-forming pharmaceutical drugs, authorise medicines which cure, and tackle real health problems like allergies, bad diet, low exercise and drug and alcohol usage.”
 
Concluding, Ken advised: “Apply these simple tests to all medication – Does it cure? Does it give genuine relief? Or is it just an excuse for selling more drugs?”
 
For more information contact:
Ken Eckersley
Campaign for the Effective Prevention & Treatment of Addiction
Arts House,
Plaw Hatch Lane,
SHARPTHORNE,
West Sussex,
RH19 4JL.
 
Tel: 01342 810151
E: mail: keneck@btopenworld.com
Web:
http://www.solutionstodrugs.com
 
Company: Campaign for the Effective Prevention & Treatment of Addiction
Contact Name: Ken Eckersley
Contact Email: keneck@btopenworld.com
Contact Phone: 01342 810151

Thursday, April 20, 2006

 

Defective Pacemakers, Heart Valves, and Defibrillators Pose New Risks

 
Defective Heart Valves, Pacemakers, and Defibrillators Propose New Risks to Weak Heart Patients

Millions of men and women have heart devices implanted to save them from heart attack not increase their risks of heart attack

New York City, New York (PRWEB) April 20, 2006 -- In the last few years, the technology of heart devices has advanced but many recalled devices are being surgically removed after the discovery of fatal defects.

Patients with heart defects or disorders of the aortic or mitral valve may need a mechanical heart valve. Mechanical heart valves simulate real heart valves to maintain the proper flow of blood into and out of the heart. These patients must take anticoagulation medicine, like Warfarin (coumadin) to prevent deadly blood clots.

Years after their removal from the market, St. Jude’s Silzone and Bjork Shiley’s Convexo-Concave heart valves are still causing serious problems in patients. To support patients with St. Jude or Bjork Shiley heart valves or other recalled heart devices, LawyersandSettlements.com accepts consumer complaints at:
Bjork Shiley Heart Valves
Or
Silzone Mechanical Heart Valves

The St. Jude Silzone Heart Valve was implanted into patients from 1997 to 2000 and was recalled due to leaking and device failure linked to serious fatal risks. One study showed that Silzone heart valves increased a patient’s risk of thrombosis/blood clot, embolism, and stroke.

Bjork Shiley distributed their Convexo-Concave (BSCC) heart valves from 1979 to 1986 but over 86,000 defective valves are still implanted in patients worldwide. These valves have remained in thousands of patients due to fatal risks associated with the surgical removal process. These valves have been linked to hundreds of deaths when the defective valve fractured and weaken the device.

About Online Legal Marketing (OLM) and
www,lawyersandsettlements.com
OLM is a privately held Internet marketing company. LawyersandSettlements.com offers up-to-date information on legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers can complete free case evaluations and subscribe to free newsletters. Justice for Everyone

Visit us at:
LawyersandSettlements.com

Contact us at:
604-608-3435

Press Contact: Scott Wurtele
Company Name: ONLINE LEGAL MARKETING LTD.
Phone: 604-608-3435
Website:  L
awyersandsettlements.com/case/bjork_shiley_heart_valves


Tuesday, April 18, 2006

 

Pharmacy Packs Pill Perfectly, Bans Bulk Bottles

PrairieStone Pharmacy Introduces the Nation's First and Only Retail Drug Packaging Solution that Pre-Sorts Meds into Easy-to-Use Packets
 
PrairieStone Pharmacy's DailyMed(TM) is the first and only retail drug packaging solution that pre-sorts multiple prescriptions, over-the-counter medications, and vitamins into easy-to-use single-dose packets. By eliminating the traditional pill bottle, DailyMed makes it easier for patients to take the right medications at the right time and better manage their health conditions. (Photo: PrairieStone Pharmacy)
 
MINNEAPOLIS--(BUSINESS WIRE)--April 18, 2006-- DailyMed(TM) Makes It Easier Than Ever for Patients and Caregivers to Ensure the Right Drug is Taken at the Right Time
 
In response to growing concerns and alarming statistics related to Americans' failure to follow prescription drug regimens, PrairieStone Pharmacy, the nation's most innovative retail pharmacy chain, today introduced DailyMed, the first and only retail drug packaging solution that pre-sorts multiple prescriptions, over-the-counter medications, and vitamins into easy-to-use single-dose packets.
 
Prescription drugs continue to be the most cost-effective therapy available to improve quality of life and treat a significant number of both common and advanced ailments. But as Americans take more prescription drugs every day, it is becoming more difficult for many to take the right medications at the right time--especially with an aging population. In fact, failing to take prescription drugs as prescribed has become so rampant and well documented that it can be linked to 125,000 deaths in the U.S. last year alone, 10 percent of all hospital admissions, 23 percent of all nursing home admissions, $100 billion in direct health care costs, and $1.5 billion in lost patient earnings.
 
"There's a real health care crisis taking place all across America, and it's called non-compliance," said Marvin Richardson, R.Ph., president and CEO of PrairieStone Pharmacy. "DailyMed is the only retail drug packaging solution in the nation that addresses this crisis with an inexpensive, easy-to-use, and effective solution that pre-sorts a patient's medications into single dose packets. With DailyMed, we can finally say goodbye to all those pill bottles and those confusing pill sorters."
 
According to Richardson, the average American between the ages of 65 and 69 takes an estimated 14 different prescription medications each year. That number increases to 18 different prescriptions for Americans between the ages of 80 and 84. And according to the National Council on Patient Information and Education, the average number of annual prescriptions per elderly person is estimated to reach 38.5 by 2010.
 
"The problem isn't just non-compliance in and of itself," said Richardson. "The problem is what that non-compliance leads to--hospital admissions, nursing home admissions, increased health care costs, and even death. The problem is that no one is addressing medication mismanagement. The problem is a failure on the part of retail pharmacy as a whole to provide better patient outcomes. By simply changing how we package medications, PrairieStone Pharmacy is mitigating many of these problems and providing a long-awaited and life-changing solution."
 
The goal of DailyMed is to improve the lives of patients who use the dispensing system and the lives of their caregivers. It does this not only by making it easier for patients to take their medications and thereby better manage their health conditions, but also by allowing PrairieStone pharmacists to review their entire drug profile and identify drug interactions, lower cost alternatives, or duplicate therapies.
 
Nathan Synder has experienced the benefits of DailyMed first-hand. His grandparents were taking 17 prescriptions between them, including over-the-counter medications and vitamins. But Nathan noticed their health declining and soon realized they weren't taking all of their medications.
 
"It was very clear to me that I had to get involved. My grandparents had eight and nine different pill bottles to open every day--some pills had to be taken together, some had to be taken with food, some had to be taken one hour after another," said Nathan. "I couldn't even figure out what pills they needed to take when, so it's no wonder they couldn't. With DailyMed, all their medications were pre-sorted for them, so we didn't have to play guessing games anymore. It was such a relief for me to know that my grandparents were taking their medications correctly."
 
DailyMed is approved by the Minnesota Board of Pharmacy and is available in most states by calling 1-800-973-1955. Patients in Minnesota can visit any PrairieStone Pharmacy located within Lunds Markets and Byerly's to sign up for DailyMed.
 
About PrairieStone Pharmacy
Founded in 2003, PrairieStone Pharmacy is one of the nation's fastest growing retail pharmacy chains. Offering a unique model that relies on state-of-the-art technology and automation, the company prides itself on placing its pharmacists closer to its customers as a way to offer exceptional customer service and care. With the launch of its patent-pending DailyMed solution, PrairieStone hopes to further extend its mission of improving retail pharmaceutical care. For more information on PrairieStone Pharmacy, visit
www.PrairieStoneRx.com.
 
Contacts
Patty Gibbs & Company PR
Patty Gibbs, 651-653-7302
pattygibbsco@aol.com

Monday, April 17, 2006

 

Heart Attack and Stroke Allegedly Linked Ortho Evra Birth Control Patch

 
Ortho Evra Birth Control Patch Allegedly Linked to Heart Attack and Stroke

With 60% more estrogen than birth control pills, the health risks of Ortho Evra Patch are increased

New York City, New York  - April 17, 2006 -- The popular, widely promoted birth control patch contains more hormones than the traditional birth control pill and these hormones, progestin, estrogen, and norelgestromin, are delivered directly into the blood stream via a transdermal skin patch.

Whether caused by the high levels of hormones or the delivery method, Ortho Evra has been linked to blood clots, heart disease, stroke, and death in young adult women.

With reports of women dying from unexpected heart problems, the FDA recently asked the maker of Ortho Evra to revise the label to warn against the risk of blood clot, stroke, or heart attack. A woman’s risk of these side effects also increases with age, smoking habits, and pre-existing conditions such as diabetes, high blood pressure, or high cholesterol.

A leading law firm, advertising on LawyersandSettlements.com, offers free case evaluations to women who have suffered blood clots, stroke, or other side effects from Ortho Evra; for more information, go to:
www,lawyersandsettlements.com/case/ortho_evra

About Online Legal Marketing (OLM)
OLM is a privately held Internet marketing company. LawyersandSettlements.com offers up-to-date information on legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers can complete free case evaluations and subscribe to free newsletters.

Visit us at:
www,
lawyersandsettlements.com

Contact us at:
1-604-608-3435

###

Press Contact: Scott Wurtele
Company Name: ONLINE LEGAL MARKETING LTD.
Phone: 604-608-3435 
www,lawyersandsettlements.com/case/ortho_evra


Saturday, April 15, 2006

 

New Magazine On Consumer-Focused Healthcare

 
ONE Magazine Launched New Quarterly: Smart Step in Consumer-Focused Healthcare

A new consumer publication – ONE – has launched this month, instantly becoming one of metro Denver’s largest circulation magazines. The 300,000-circulation quarterly magazine focuses on health and well being and establishes HCA-HealthONE LLC as the leading source of healthcare information for area consumers.

DENVER (PRWEB) April 15, 2006 -- A new consumer publication – ONE – has launched this month, instantly becoming one of metro Denver’s largest circulation magazines. The 300,000-circulation quarterly magazine focuses on health and well being and establishes HCA-HealthONE LLC as the leading source of healthcare information for area consumers.

ONE is the insider’s guide to current health and wellness trends. The first issue contains articles of interest to all ages and genders: from knifeless brain surgery to preventing sports injuries and much more. The next issue, due out in January, will continue to serve as a road map for asking the right questions and finding the right answers about healthcare today.

“Until ONE, people in metro Denver haven’t had a reliable, single source devoted solely to medical information and healthcare news,” says Linda Kanamine, HealthONE Vice President of Public Affairs. “I think they’ll be surprised to read about the amazing array of research, treatments and medical technologies that exist right here in their own backyards.”

HealthONE partnered with Wiesner Publishing LLC to publish the glossy, four-color magazine. As the first publication of its kind in Denver, Publisher Maureen Regan says, “It is so encouraging to be a partner with a company that is breaking ground in their efforts to connect with people in their communities and provide information that will ultimately make us all smarter healthcare consumers.”

The medical industry is constantly changing with new technologies, new treatments and new preventions developing every day. “The need to stay informed and to become better educated has never been greater,” Kanamine adds. “ONE was created to be a support system for Coloradans to navigate the complicated world of staying healthy.”

In addition to copies mailed to homes, the magazine can be obtained at Cherry Creek Shopping Center, the Denver Chamber of Commerce or any HealthONE hospital.

HealthONE is the largest healthcare system in the metro Denver area with 8,700 employees and 3,000 affiliated physicians. Recently named Colorado's "Best Company for Working Families -- large business category," the health system was created in 1995 as a 50/50 joint venture between various affiliates of HCA and HealthONE Alliance, a Colorado nonprofit organization.

HealthONE includes: The Medical Center of Aurora and Centennial Medical Plaza; North Suburban Medical Center; Presbyterian/St. Luke's Medical Center; Rose Medical Center; Sky Ridge Medical Center; Spalding Rehabilitation Hospital; Swedish Medical Center; seven surgical centers; more than 35 occupational medicine/rehabilitation, Broncos Sports Medicine, specialty, and outpatient diagnostic imaging clinics; as well as AIRLIFE, which provides critical care air and ground transportation for the HealthONE system.

# # #

Press Contact: Amy Santisi
Company Name: HealthONE
Email: email protected from spam bots
Phone: 303-584-6038
Website:
http://www.onemagazineonline.net


Wednesday, April 12, 2006

 

Eye-Opening Film On Pharmaceutical Industry

 
Filmmaker Delivers One-two Punch to Big Pharma

Filmmaker Kathleen Slattery-Moschkau's film, Side Effects, is causing a stir across the nation for its insider's look at the pharmaceutical industry. For those who missed the storm of buzz during its rolling theatrical release, Side Effects will be released to DVD May 16 and sold in Borders, Best Buy and Circuit City stores across the United States, and online at www.sideeffectsthemovie.com and www.Amazon.com. Side Effects, which has been heralded as a light and entertaining approach to a heavy issue, examines the pill-pushing tactics of big pharma, and stars Katherine Heigl, sexy intern on ABC’s award-winning drama, Grey’s Anatomy.

LOS ANGELES, CA (PRWEB) April 12, 2006 -– Causing a stir across the nation, sold-out audiences have flocked to see the eye-opening indie film that the pharmaceutical industry wishes would go away. For those who missed the storm of buzz during its rolling theatrical release, Side Effects will be released to DVD May 16 and sold in Borders, Best Buy and Circuit City stores across the United States and online at www.sideeffectsthemovie.com and www.Amazon.com.

Side Effects, which has been heralded as a light and entertaining approach to a heavy issue, is an insider’s look at the pharmaceutical industry and stars Katherine Heigl, sexy intern on ABC’s award-winning drama, Grey’s Anatomy.

Since its world premiere a year ago, writer/director Kathleen Slattery-Moschkau continues to be stunned by the level of interest from consumers, physicians and the holistic community. The film is making a tremendous impact because Slattery-Moschkau speaks from experience. Based on her decade working as a drug sales rep, Side Effects examines the pill-pushing tactics of the pharmaceutical industry’s leading companies.

After releasing Side Effects to the public, Slattery-Moschkau went on to make Money Talks: Profits Before Patient Safety, a revealing documentary that examines the ethics of marketing within the drug industry, which will be available May 16, online only.

True to her position since the beginning, Slattery-Mosckau continues to take a reasoned approach to the issues surrounding the industry. “We need to acknowledge that we need prescription medications, but understand that the current system is broken—-these are the first steps toward progress,” says Slattery-Moschkau.

With Michael Moore’s film Sicko due out in fall of 2006, the pharmaceutical industry will have its hands full this year. “For me, this is not a witch hunt,” says Slattery-Moschkau. “It’s about accountability, raising awareness, and leveling the playing field—the beauty of a free market system.”

To arrange an interview with Kathleen Slattery-Moschkau, contact Cari Reisinger of Hummingbird Pictures at (414) 264-1065.

###

Press Contact: Cari Reisinger
Company Name: HUMMINGBIRD PICTURES
Email: email protected from spam bots
Phone: 414-264-1065
Website:
www.sideeffectsthemovie.com

__________________________________________________________
Free trade and professional industry magazines are available at
http://www.consultant-directory.tradepub.com
__________________________________________________________
Merck Vioxx is one of many current hot topics, find information at:
http://www.vioxx-search-engine.com
__________________________________________________________
Lung Cancer caused by asbestos exposure is known as
Mesothelioma. Learn more about this killer cancer.
Visit http://www.Mesothelioma-Search-Engine.com
__________________________________________________________
JR Roberts, a Security Expert Witness can help you prosecute 
 
or defend your criminal or negligent liability case in court.
http://www.jrrobertssecurity.com/
__________________________________________________________
http://www.legal-search-engine.com
http://www.drug-store-directory.com
__________________________________________________________

 

 


Saturday, April 08, 2006

 

Public Denied Access To Lawyer Review Site

 
JudicalCheck.com Causes Controversy in Legal Community

JudicialCheck an online website for the legal community is being threatened with shutdown by attorneys who are afraid their discipline records and incompetence will be exposed. JudicialCheck.com is a powerful online tool exclusively for the legal profession where members can post honest reviews of attorneys and judges and access the latest information available about State Bar disciplinary actions.

April 8, 2006 -- Recently, JudicalCheck.com has been threatened with lawsuits by attorneys who have been reviewed by their peers. The complaining attorneys are apparently reading for the first time the “truth” about how their colleagues perceive them. One lawyer in San Mateo, California, after reading a negative review about himself decided that rather than trying to address the factual problems that were the root of his negative rating, it would be easier to threaten to sue and shut down JudicialCheck.com. This is not the first time that JudicialCheck.com has been threatened by lawyers unhappy with having such information readily available.

“Although we have been threatened many times, JudicialCheck.com will continue to operate,” commented Richard Oberreiter, a JudicialCheck co-founder, “the information found on JudicialCheck.com is a valuable tool for law professionals as they can research themselves and others and find out what people really think of them. We will not shut it down because some attorneys don’t like negative feedback.”

Before JudicialCheck.com the only way to find out about another attorney or judge was through ineffective word-of-mouth, outdated print publications and fluff pieces in local legal newspapers. With JudicialCheck.com any licensed legal professional can find out about their adversaries and be prepared in advance.

Press Contact: Richard Oberreiter
Company Name: JudicialCheck.com, Inc.
Phone: 949 887 8396
Website:
www.judicialcheck.com


 

Merck Vioxx Victim Wins $4.5 Million

 
Weitz & Luxenberg Wins $4.5 Million on Behalf of Vioxx Victim

Attorney Robert Gordon of Manhattan personal injury law firm Weitz & Luxenberg, P.C. (www.weitzlux.com) secured a $4.5 million verdict for John McDarby, a wheelchair-bound diabetic, who suffered a heart attack after taking the popular recalled painkiller, Vioxx.

New York, NY  - April 5, 2006 – Attorney Robert Gordon of Manhattan personal injury law firm Weitz & Luxenberg, P.C. (www.weitzlux.com) secured a $4.5 million verdict for John McDarby, a wheelchair-bound diabetic, who suffered a heart attack after taking the popular recalled painkiller, Vioxx (case # ATL L 1296-05).

Attorney Jerry Kristal, also of Weitz & Luxenberg, served as co-trial counsel.

The Atlantic City, New Jersey jury found that pharmaceutical giant Merck, Inc. failed to satisfactorily warn Mr. McDarby and the trial’s other plaintiff, Thomas Cona, that Vioxx increased their risk of heart attacks, strokes, and other serious cardiovascular side effects in long-term Vioxx use.

Mr. McDarby used Vioxx daily for four years.

While the jury found that Vioxx did not play a role in Mr. Cona’s heart attack, they did agree that Merck was guilty of consumer fraud, awarding $3,969 to Mr. McDarby and $45 to Mr. Cona. The jury found Merck both deceived doctors about Vioxx’s cardiovascular risks, and deliberately hid information about those risks from physicians.

Mr. Gordon and Mr. Cona’s lawyer, Mark Lanier, argued that Vioxx was released to the American marketplace with inadequate testing, that Merck ignored warning signs about the drug’s safety, failed to alert the FDA and federal regulators of its dangers, and spent hundreds of millions of dollars aggressively marketing a drug the company knew to be unsafe.

`Merck thought that this was going to be an easy win for them, and we said this is exactly the type of person who needed to be protected from Vioxx,'' said Mr. Gordon.

Vioxx was first marketed in 1999, and its sales grew to $2.5 billion annually. 20 million patients took Vioxx, which was billed as a “super aspirin,” until it was recalled in September of 2004.

There are now 10,000 pending Vioxx lawsuits, and Merck has set aside $970 million to fight each one individually.

Mr. McDarby collapsed when he suffered his heart attack on April 15, 2004. He broke a hip when he fell. Mr. Gordon sought compensatory damages for Mr. McDarby for his heart attack and hip fracture.

While Merck tried to argue that Mr. McDarby, an ex-smoker, had pre-existing risk factors, such as diabetes, that made him a likely candidate for a heart attack, Mr. Gordon argued that Merck was negligent in not properly alerting prescribing physicians and patients with someone like Mr. McDarby’s risk factors of what the dangers of taking Vioxx were.

Mr. Gordon described Mr. McDarby as ``exactly the type of person who needed to be protected from Vioxx.'' During his closing argument, Mr. Gordon demanded, ``When they say diabetes caused it, well, why didn't they warn about diabetes? When they say that age caused it why didn't you warn about older people?''

It is possible that Mr. McDarby’s verdict will be increased. On April 6, 2006, the jury will weigh punitive damages against Merck, after finding Vioxx played a “substantial” role in Mr. McDarby’s heart attack.

Mr. Gordon is Weitz & Luxenberg’s chief trial lawyer and a shareholder at the firm. He has served as lead trial counsel in several consolidated cases involving numerous plaintiffs and multiple defendants.

Mr. Gordon has obtained jury verdicts in excess of $392,000,000. He was appointed by the Honorable Shira Scheindlin, Southern District of New York, as Co-lead Counsel in the MTBE Litigation (MDL 1358).

He was also appointed by the Honorable Sam Pointer, Northern District of Alabama, to the Plaintiffs Steering Committee in the Breast Implant Multi-District Litigation (MDL 926), in which he served as Co-chair of the Science Subcommittee.

Mr. Gordon was also appointed by the Honorable Lewis Kaplan, Southern District of New York, to the Plaintiffs Steering Committee in the Rezulin Multi-District Litigation (MDL 1348) and by the Honorable Helen Freedman, New York State Supreme Court, as Co-liaison Counsel to the PSC and MDL in the consolidated state Rezulin litigation.

He was also appointed by the Honorable Michael J. Davis, District of Minnesota, to the Baycol Liaison Advisory Committee and the Compensation Subcommittee (MDL 1431). He lectures nationally and has published numerous articles on various aspects of complex litigation.

Mr. Gordon has been appointed to both the Scientific and Medical Integrity Committee and the ATLA List Committee of the Association of Trial Lawyers of America as well as the Committee on Tort Litigation of the Association of the Bar of the City of New York.

Formerly an assistant district attorney in the felony jury unit of the Philadelphia District Attorney's Office and an adjunct professor at Temple University, Mr. Gordon was honored by the National Law Journal in 1995 as one of the top forty attorneys in the country under the age of 40.

Weitz & Luxenberg is one of America’s leading personal injury law firms. Located in downtown Manhattan, the firm employs 62 attorneys and over 250 support professionals.

Weitz & Luxenberg is seeking to represent individuals who have suffered heart attacks, strokes, and other cardiovascular events after taking Vioxx. Interested parties may visit the firm’s corporate website at http://weitzlux.com/vioxxresourcecenter_1051.html, or call Weitz & Luxenberg at 1 (800) 476-6070 for more information and to receive a free case evaluation for a Vioxx lawsuit.

Contact: Jonathan Jaffe
Company Name: WEITZ & LUXENBERG, P.C.
Phone: 2125585682
Website:
www.weitzlux.com

_______________________________________________________
Free trade and professional industry magazines are available at
http://www.consultant-directory.tradepub.com
_______________________________________________________
The Vioxx Search Engine provides listings of sites that provide
medical and legal information on Merck Vioxx:
http://www.vioxx-search-engine.com
_______________________________________________________
Lung Cancer caused by asbestos exposure is known as
Mesothelioma. Learn more about this killer cancer.
Visit
http://www.Mesothelioma-Search-Engine.com
_______________________________________________________
JR Roberts, a Security Expert Witness can help you prosecute
 
or defend your criminal or negligent liability case in court.
http://www.jrrobertssecurity.com/
__________________________________________________
http://www.legal-search-engine.com
http://www.drug-store-directory.com
__________________________________________________


Tuesday, April 04, 2006

 

Insecure About Past Success, 3M Wants Direction From Pharmaceutical Company

3M to Explore Strategic Alternatives for its Branded Pharmaceuticals Business
 
ST. PAUL, Minn.--(BUSINESS WIRE)--April 4, 2006--3M today announced that it is exploring strategic alternatives for its global branded pharmaceuticals business and immune response modifier platform.
 
3M Pharmaceuticals Division, part of 3M's Health Care business, discovers, develops, manufactures and sells branded drug products related to dermatology, women's health, cardiology and respiratory medicine. Its most well-known brands are Aldara, Difflam, Duromine, Tambocor, Maxair, Metrogel-Vaginal and Minitran. There are approximately 1,500 employees in the business worldwide.
 
3M's branded pharmaceuticals business has been very successful. However, in today's very competitive pharmaceutical marketplace, continued success requires broad pipelines of new drugs, significant investments, and a longer term risk-reward business model than applies to most other 3M businesses.
 
"The best way for this business to grow is for it to be free to pursue separate strategies under the direction of a dedicated pharmaceutical industry company with a business model better suited to maximize its potential," said Brad Sauer, executive vice president, 3M Health Care. "We believe our branded pharmaceuticals business is a valuable asset and there are more opportunities for technology and market synergies with a company other than 3M."
 
To assist the company in exploring its strategic alternatives, 3M has retained Goldman, Sachs & Co. as its investment banker.
 
3M Health Care, one of 3M's six major business segments, provides world-class innovative products and services to help health care professionals improve the practice and delivery of patient care. 3M will continue to grow its vibrant Health Care businesses globally serving multiple market segments.
 
About 3M -- A Global, Diversified Technology Company
 
Every day, 3M people find new ways to make amazing things happen. Wherever they are, whatever they do, the company's customers know they can rely on 3M to help make their lives better. 3M's brands include icons such as Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti. Serving customers in more than 200 countries around the world, the company's 69,000 people use their expertise, technologies and global strength to lead in major markets including consumer and office; display and graphics; electronics and telecommunications; safety, security and protection services; health care; industrial and transportation.
 
Aldara, Difflam, Duromine, Tambocor, Maxair, Metrogel-Vaginal, Minitran, Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti are trademarks of 3M.
 
Contacts
3M, St. Paul
Media Contacts:
Donna Fleming, 651-736-7646
or
Investor Contacts:
Mark Colin, 651-733-8206
or
Bruce Jermeland, 651-733-1807

This page is powered by Blogger. Isn't yours?

vertical search engines | niche search engines | search engines | vioxx | search-engines